Lightspeed Commerce에 대한 매도 수량은 투자자에게 Lightspeed Commerce의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Lightspeed Commerce (NYSE:LSPD) 주식, 공매도 수량 보고

Lightspeed Commerce

Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, New Zealand, United Kingdom, Australia, Germany, and other countries. It derives a majority of its revenue from the United States.

Lightspeed POS

Tesla Bull Says There Are ‘No Winners’ With Trump’s Auto Tariffs, Calls It ‘Pure Chaos’ For Global Supply Chains

Government

Markets

Analyst Ratings

BIGC

LSPD

SHOP

애널리스트에 따르면 이커머스 소프트웨어 공급업체 및 플랫폼인 쇼피파이(NASDAQ:SHOP), 빅커머스 홀딩스(NASDAQ:BIGC), 그리고 라이트스피드 커머스(TSE:LSPD)가 최근 관세 조치에 &#39;가장 많이 노출&#39;된 것으로 나타났다. 

트럼프의 &#39;소액 면세&#39; 종료...쇼피파이, 빅커머스, 라이트스피드에 악재

benzinga_deal_dispatch2

News

AMPS

BLCO

BTBT

FYBR

LBPH

MSGM

NVAX

PDCO

SNDR

TCEHY

UBSFF

USAP

새로이 등장한 블록 치과용품 제조업체인 패터슨 컴퍼니즈(NASDAQ:PDCO)가 주주 가치를 높이기 위해 매각 또는 합병을 포함한 전략적 옵션을 모색 중이라고 목요일 발표했다. 이 회사는 거래 과정을 2분기 재무 보고서의 일환으로 공개했다.

딜 디스패치: 유비소프트는 매각 협상 중, 패터슨은 매각 탐색 중, 프로마의 레카로 인수 등

Lightspeed Commerce Inc. Subordinate Voting Shares

Lightspeed Commerce Inc

USAU

U.S. Gold Corp. Provides Recent Warrant Exercises Update; Exercised 1,864,668 Warrants For Gross Proceeds ~$7.3M

<p>Entera Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTX#NASDAQ">ENTX</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 20 percent decrease over losses of $(0.05) per share from the same period last year.  The company reported $42.00 thousand in sales this quarter.</p>


Earnings

Earnings Beats

ENTX

Entera Bio Q1 EPS $(0.06) Beats $(0.07) Estimate, Sales $42.00K

<p>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) reported quarterly losses of $(0.25) per share. This is a 98.87 percent increase over losses of $(22.14) per share from the same period last year.</p>


ALLR

Allarity Therapeutics Q1 EPS $(0.25) Up From $(22.14) YoY

<p>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) reported quarterly losses of $(0.23) per share. This is a 66.67 percent increase over losses of $(0.69) per share from the same period last year.</p>


ATHA

Athira Pharma Q1 EPS $(0.23) Up From $(0.69) YoY

<p><strong>Gualberto Hernandez to be appointed as CFO; Michael McCleary to Retire</strong></p>
<p>SAN DIEGO, May 9, 2025 /PRNewswire/ -- PriceSmart, Inc. ("PriceSmart" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSMT#NASDAQ">PSMT</a>) today announced the appointment of Gualberto Hernandez as Executive Vice President and Chief Financial Officer effective June 1, 2025. PriceSmart's current Executive Vice President and Chief Financial Officer Michael McCleary resigned by mutual agreement with the Company, but will continue to serve as an Executive Vice President of the Company through September 30, 2025. Thereafter, Mr.&nbsp;McCleary has agreed to provide consulting support of up to 40 hours per month for three months following his resignation.</p>


Management

PSMT

PriceSmart Appoints Gualberto Hernandez As Executive Vice President And CFO, Effective June 1, 2025; Michael McCleary To Retire

<p>Surrozen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRZN#NASDAQ">SRZN</a>) reported quarterly losses of $(7.43) per share which missed the analyst consensus estimate of $(1.78) by 317.42 percent. This is a 75.24 percent decrease over losses of $(4.24) per share from the same period last year.</p>


Earnings Misses

SRZN

Surrozen Q1 EPS $(7.43) Misses $(1.78) Estimate

<p>Although financial services giant <strong>Visa Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) technically represents one of the strongest names in the market on a year-to-date basis, V stock hasn't made progress since the end of February. Due to <a href="https://www.benzinga.com/25/04/45074861/us-consumer-expectations-falls-to-13-year-lows-as-recession-fears-inflation-worries-surge">uncertainties surrounding the consumer economy</a>, the equity is stuck in a holding pattern. Nevertheless, the forward-looking nature of the market suggests that the payment card company may offer the bulls an upside prospect.</p>
<p>Granted, on paper, circumstances don't look great for V stock. It's not just about consumer sentiment levels plunging to multi-year lows. On the front lines of the economy, consumers are increasingly opening their wallets to <a href="https://www.benzinga.com/news/25/04/44916124/frozen-pizza-sales-surge-like-2009-recession-as-americans-cut-back-on-dining-out-amid-economic-strain">purchase comfort foods</a>. In particular, frozen pizza sales have experienced a significant surge, which some experts believe represents a shift in consumer behavior.</p>
<p>While Visa should theoretically benefit from these purchases, with the consumer pivoting away from high dollar and high-margin products, the financial impact will likely also drag the payment card company.</p>
<p>Among the critical drivers of the economic anxiety are the tariffs. With President <strong>Donald Trump </strong>taking a direct approach to settling disagreements with key economic partners, the sharp contrast to the Biden administration has exacerbated fears tied to inflation and other chronic post-pandemic issues.</p>
<p>At the same time, bullish investors have reason to be hopeful in V stock. Recently, the U.S. and China agreed to <a href="https://www.benzinga.com/25/05/45242461/donald-trumps-trade-war-sparks-first-major-us-china-talks-scott-bessent-jamieson-greer-to-meet-chinese-delegation-in-geneva">high-level trade talks</a>, which suggests some momentum toward a deal. On a broadly related note, the Trump administration <a href="https://www.benzinga.com/25/05/45294428/wall-street-rallies-after-us-seals-first-trade-deal-you-better-go-out-and-buy-stock-trump-says">signed its first major trade agreement</a> with the United Kingdom, signaling progress.</p>
<p>Since the market doesn't trade looking through the rearview mirror, Visa could be an intriguing idea with contrarian undertones.</p>
<h2 class="wp-block-heading">Why V Stock Could Break Out of Its Consolidation Pattern</h2>
<p>As a blue-chip stalwart, Visa generally enjoys the benefit of the doubt. On any given moment, the chances that a one-week long position will be profitable is approximately 55%. That's not the biggest edge in the world but at scale, bullish speculation on V should theoretically end up being more profitable than not (assuming rational money management).</p>
<p>Still, it should be noted that the 55% figure stems from the entire distribution of sentiment regimes. Of course, that's not how capital markets operate. Instead, investors are thrown into a wild mix of fear and greed cycles. In particular cycles, the probabilities of upside can sometimes shift dramatically from the baseline.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="599" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152307/V-stock-price-chart-1024x599.jpg" alt="" class="wp-image-910704" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152307/V-stock-price-chart-1024x599.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152307/V-stock-price-chart-300x176.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152307/V-stock-price-chart-768x449.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152307/V-stock-price-chart.jpg 1027w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by TradingView</figcaption></figure></p>
<p>From a technical perspective, V stock doesn't look particularly inviting, either from a bullish or bearish angle. But from a quantitative perspective, the equity is currently printing a "6-4" sequence: six weeks of upside interspersed with four weeks of downside, with a net negative trajectory from the beginning of the period to the end.</p>
<p>Unlike standard technical analysis, where the practitioner must decipher a shape, pattern or other meaning from a scalar signal (such as moving averages), the 6-4 sequence is falsifiable. And if something is falsifiable, it can be categorized, quantified and deployed for probabilistic analysis.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152339/V-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-910708" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152339/V-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152339/V-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152339/V-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09152339/V-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure></p>
<p>Empirically, the 6-4 sequence with a net negative trajectory has flashed 16 times over the past decade. In 75% of cases, the following week's price action rises, thus incentivizing a bullish outlook. Should the positive pathway continue to dominate, investors may expect a potentially "peaky" rise to around $363 over the next 10 weeks. Should the bears take control, the downside target is around $344.</p>
<h2 class="wp-block-heading">Using the Leverage of Options for a Big Payout</h2>
<p>To be sure, a 3% lift in V stock isn't anything to write home about — but that only applies if acquiring shares in the open market. By using the leverage of options, speculators can take this small potential uptick and translate it into a much bigger payout.</p>
<p>A compelling idea to consider is the 355/360 bull call spread expiring May 30. This transaction involves buying the $355 call and simultaneously selling the $360 call, for a net debit paid of $235. Should V stock rise through the short strike price of $265, the maximum reward stands at $265, a payout of nearly 113%.</p>
<p>Why this idea is attractive centers on the response to the 6-4 sequence. Again, if the bulls take control of the wheel, V stock may rise above $361, which would be more than enough to trigger the max payout at expiration. However, the exact timing of price action will always be a crapshoot. Therefore, the May 30 expiration date provides some time buffer for the trade to materialize.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/05/45268035/cnk-stock-short-squeeze-fervor-fade-bear-put-spread"><strong>Options Corner: Cinemark&#8217;s Short Squeeze Won&#8217;t Prevent The Credits From Eventually Rolling</strong></a></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Equities

Long Ideas

Options

Options Corner: Visa Flashes Potential Rebound Signal Amid Thawing Trade War Tensions

<p>Hawaiian Electric Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HE#NYSE">HE</a>) reported quarterly earnings of $0.23 per share which met the analyst consensus estimate. This is a 11.54 percent decrease over earnings of $0.26 per share from the same period last year.  The company reported $744.07 million in sales this quarter. This is a 6.05 percent decrease over sales of $792.01 million the same period last year.</p>


Hawaiian Electric Indus Q1 Adj. EPS $0.23, Inline, Sales $744.07M Down From $792.01M YoY

<p>HF Foods Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFFG#NASDAQ">HFFG</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate HF Foods Group to report an <strong>earnings per share</strong> (EPS) of $0.13.</p>
<p>HF Foods Group bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<p>Here's a look at HF Foods Group's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.11</td>
<td>-0.07</td>
<td>0</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>28.999999999999996%</td>
<td>-1.0%</td>
<td>3.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Market Performance of HF Foods Group's Stock</h3>
<p>Shares of HF Foods Group were trading at $3.9 as of May 08. Over the last 52-week period, shares are up 43.04%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/HFFG/earnings"><strong>To track all earnings releases for HF Foods Group visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


HFFG

A Look Ahead: HF Foods Group's Earnings Forecast

<p>Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) today announced that its board of directors declared a quarterly cash dividend of 67 cents per share of common stock, which reflects the company's earnings growth and strong cash generation. The dividend is payable on June 30, 2025, to shareholders of record as of the close of business on May 23, 2025.</p>


Dividends

Marriott International Raises Quarterly Cash Dividend From $0.63 To $0.67 Per Share

<p>FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate FiscalNote Holdings to report an <strong>earnings per share</strong> (EPS) of $-0.04.</p>
<p>Investors in FiscalNote Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company missed EPS by $0.06, which was followed by a 4.38% drop in the share price the next day.</p>
<p>Here's a look at FiscalNote Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.04</td>
<td>-0.10</td>
<td>0.01</td>
<td>-0.17</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.10</td>
<td>-0.11</td>
<td>-0.09</td>
<td>-0.12</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>-13.0%</td>
<td>-4.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821195_0.png" alt="eps graph" /></p>
<h3>Market Performance of FiscalNote Holdings's Stock</h3>
<p>Shares of FiscalNote Holdings were trading at $0.6437 as of May 08. Over the last 52-week period, shares are down 55.04%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<h3>Insights Shared by Analysts on FiscalNote Holdings</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding FiscalNote Holdings.</p>
<p>With 5 analyst ratings, FiscalNote Holdings has a consensus rating of Buy. The average one-year price target is $2.7, indicating a potential 319.45% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of  and RCM Technologies, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for RCM Technologies, with an average 1-year price target of $30.0, suggesting a potential 4560.56% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for  and RCM Technologies, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>FiscalNote Holdings</td>
<td>Buy</td>
<td>-14.00%</td>
<td>$19.40M</td>
<td>-13.63%</td>
</tr>
<tr>
<td>RCM Technologies</td>
<td>Buy</td>
<td>8.28%</td>
<td>$21.57M</td>
<td>9.03%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>FiscalNote Holdings ranks lower in Revenue Growth compared to its peers. It also lags behind in Gross Profit margin. However, it outperforms in Consensus rating and Return on Equity.</p>
<h3>All You Need to Know About FiscalNote Holdings</h3>
<p>FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.</p>
<h3>FiscalNote Holdings: A Financial Overview</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Challenges:</strong> FiscalNote Holdings's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-14.0%</strong>. This indicates a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-45.41%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> FiscalNote Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-13.63%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> FiscalNote Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-4.03%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> FiscalNote Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.77</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/NOTE/earnings"><strong>To track all earnings releases for FiscalNote Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


NOTE

A Peek at FiscalNote Holdings's Future Earnings

<p><strong>On May 5, 2025, the Audit Committee (the "Audit Committee") of the Board of Directors of Digital Ally, Inc. (the "Company") approved the dismissal of RBSM LLP ("RBSM") as the Company's independent registered public accounting firm.</strong></p>
<p>&nbsp;</p>
<p><strong>The reports of RBSM on the Company's consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that RBSM's reports on the consolidated financial statements of the Company as of and for the years December 31, 2024 contained an explanatory paragraph stating that "The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has incurred substantial operating losses and will require additional capital to continue as a going concern. This raises substantial doubt about the Company's ability to continue as a going concern. Management's plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty."</strong></p>
<p>&nbsp;</p>
<p><strong>During the fiscal years ended December 31, 2024 and 2023, and through May 5, 2025, there have been no "disagreements" (as defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions) with RBSM on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements if not resolved to the satisfaction of RBSM would have caused RBSM to make reference thereto in its reports on the consolidated financial statements for such years. During the fiscal years ended December 31, 2024 and 2023, and through May 5, 2025, there have been no "reportable events" (as defined in Item 304(a)(1)(v) of Regulation S-K).</strong></p>
<p>&nbsp;</p>
<p><strong>The Company provided RBSM with a copy of the disclosure it is making herein in response to Item 304(a) of Regulation S-K, and requested that RBSM to furnish the Company with a copy of its letter addressed to the Securities and Exchange Commission (the "SEC"), pursuant to Item 304(a)(3) of Regulation S-K, stating whether or not RBSM agrees with the statements related to them made by the Company in this report. A copy of RBSM's letter to the SEC dated May 7, 2025 is attached as Exhibit 16.1 to this report.</strong></p>
<p>&nbsp;</p>
<p><strong>(b) Appointment of New Independent Registered Public Accounting Firm</strong></p>
<p>&nbsp;</p>
<p><strong>On May 5, 2025, the Audit Committee approved the appointment of Victor Mokuolu CPA PLLC ("Mokuolu") as the Company's new independent registered public accounting firm, effective immediately, to perform independent audit services for the fiscal year ending December 31, 2025. During the fiscal years ended December 31, 2024 and 2023 and through May 5, 2025, neither the Company, nor anyone on its behalf, consulted Mokuolu regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to the consolidated financial statements of the Company, and no written report or oral advice was provided to the Company by Mokuolu that was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a "disagreement" (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a "reportable event" (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).</strong></p>


DGLY

Digital Ally Replaces Auditor RBSM With Victor Mokuolu CPA Despite No Disputes, Amid Going Concern Warning

<p><strong>FibroGen</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that FibroGen will report an <strong>earnings per share</strong> (EPS) of $-0.10. </p>
<p>The market awaits FibroGen's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS beat by $0.12, leading to a 21.8% drop in the share price on the subsequent day.</p>
<p>Here's a look at FibroGen's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.20</td>
<td>-0.30</td>
<td>-0.26</td>
<td>-0.42</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.08</td>
<td>-0.17</td>
<td>-0.16</td>
<td>-0.33</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-22.0%</td>
<td>-14.000000000000002%</td>
<td>5.0%</td>
<td>18.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821173_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of FibroGen were trading at $0.3194 as of May 08. Over the last 52-week period, shares are down 74.54%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/FGEN/earnings"><strong>To track all earnings releases for FibroGen visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


FGEN

A Preview Of FibroGen's Earnings

<p>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Coherus BioSciences will report an <strong>earnings per share</strong> (EPS) of $-0.15.</p>
<p>Investors in Coherus BioSciences are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS missed by $0.15 in the last quarter, leading to a 0.96% increase in the share price on the following day.</p>
<p>Here's a look at Coherus BioSciences's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.13</td>
<td>-0.12</td>
<td>-0.16</td>
<td>-0.24</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.28</td>
<td>-0.01</td>
<td>-0.14</td>
<td>-0.32</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>13.0%</td>
<td>11.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821155_0.png" alt="eps graph" /></p>
<h3>Performance of Coherus BioSciences Shares</h3>
<p>Shares of Coherus BioSciences were trading at $0.9923 as of May 08. Over the last 52-week period, shares are down 53.6%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CHRS/earnings"><strong>To track all earnings releases for Coherus BioSciences visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CHRS

Earnings Preview: Coherus BioSciences

WIIM

ARRY

CSIQ

FSLR

SEDG

SPWR

Shares of solar stocks are trading higher following a report suggesting Republican lawmakers support tax credits in former President Biden's Inflation Reduction Act legislation.

<p>Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Microvision will report an <strong>earnings per share</strong> (EPS) of $-0.06.</p>
<p>The announcement from Microvision is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company missed EPS by $0.05, which was followed by a 6.47% drop in the share price the next day.</p>
<p>Here's a look at Microvision's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.09</td>
<td>-0.10</td>
<td>-0.13</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.14</td>
<td>-0.07</td>
<td>-0.11</td>
<td>-0.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>3.0%</td>
<td>8.0%</td>
<td>-25.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821093_0.png" alt="eps graph" /></p>
<h3>Market Performance of Microvision's Stock</h3>
<p>Shares of Microvision were trading at $1.15 as of May 08. Over the last 52-week period, shares are down 3.2%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Opinions on Microvision</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Microvision.</p>
<p>A total of 4 analyst ratings have been received for Microvision, with the consensus rating being Buy. The average one-year price target stands at $2.5, suggesting a potential 117.39% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of  and SmartRent, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for SmartRent, with an average 1-year price target of $1.45, suggesting a potential 26.09% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>Within the peer analysis summary, vital metrics for  and SmartRent are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microvision</td>
<td>Buy</td>
<td>-67.65%</td>
<td>$-2.47M</td>
<td>-54.36%</td>
</tr>
<tr>
<td>SmartRent</td>
<td>Neutral</td>
<td>-18.11%</td>
<td>$13.56M</td>
<td>-14.88%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Microvision ranks lower in Revenue Growth compared to its peer. It also lags in Gross Profit and Return on Equity. Overall, Microvision's performance is below its peer in all key metrics analyzed.</p>
<h3>Discovering Microvision: A Closer Look</h3>
<p>Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.</p>
<h3>Financial Milestones: Microvision's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Microvision's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-67.65%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Microvision's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-1888.18%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Microvision's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-54.36%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Microvision's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-29.75%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Microvision's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.06</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/MVIS/earnings"><strong>To track all earnings releases for Microvision visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MVIS

Insights Ahead: Microvision's Quarterly Earnings

<p><strong>Assertio Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Assertio Holdings will report an <strong>earnings per share</strong> (EPS) of $-0.06. </p>
<p>Anticipation surrounds Assertio Holdings's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company beat EPS by $0.01, which was followed by a 7.46% drop in the share price the next day.</p>
<p>Here's a look at Assertio Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.04</td>
<td>-0.05</td>
<td>-0.03</td>
<td>-0.03</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.03</td>
<td>0.03</td>
<td>0.02</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-7.000000000000001%</td>
<td>-8.0%</td>
<td>-12.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821078_0.png" alt="eps graph" /></p>
<h3>Assertio Holdings Share Price Analysis</h3>
<p>Shares of Assertio Holdings were trading at $0.6394 as of May 08. Over the last 52-week period, shares are down 41.89%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ASRT/earnings"><strong>To track all earnings releases for Assertio Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ASRT

A Look at Assertio Holdings's Upcoming Earnings Report

<p>Clarke (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CKI#TSX">CKI</a>) reported quarterly losses of $(0.17) per share. This is a 200 percent decrease over earnings of $0.17 per share from the same period last year.  The company reported $17.70 million in sales this quarter. This is a 21.23 percent increase over sales of $14.60 million the same period last year.</p>


TSX:CKI

Clarke Q1 EPS $(0.17) Down From $0.17 YoY, Sales $17.70M Up From $14.60M YoY

<p><strong>Landsea Homes</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Landsea Homes will report an <strong>earnings per share</strong> (EPS) of $-0.03. </p>
<p>Landsea Homes bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS missed by $0.22, leading to a 8.37% increase in the share price on the subsequent day.</p>
<p>Here's a look at Landsea Homes's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.47</td>
<td>0.15</td>
<td>0.10</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.25</td>
<td>0.44</td>
<td>0.36</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>8.0%</td>
<td>-2.0%</td>
<td>-7.000000000000001%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821024_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Landsea Homes were trading at $6.1 as of May 08. Over the last 52-week period, shares are down 34.83%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/LSEA/earnings"><strong>To track all earnings releases for Landsea Homes visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LSEA

An Overview of Landsea Homes's Earnings

<p><strong>Tango Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Tango Therapeutics will report an <strong>earnings per share</strong> (EPS) of $-0.38. </p>
<p>Investors in Tango Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.01, leading to a 5.05% drop in the share price the following trading session.</p>
<p>Here's a look at Tango Therapeutics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.34</td>
<td>-0.37</td>
<td>-0.34</td>
<td>-0.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.35</td>
<td>-0.27</td>
<td>-0.24</td>
<td>-0.35</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>-13.0%</td>
<td>2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746821016_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Tango Therapeutics were trading at $1.1 as of May 08. Over the last 52-week period, shares are down 84.47%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Insights on Tango Therapeutics</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Tango Therapeutics.</p>
<p>Analysts have given Tango Therapeutics a total of 1 ratings, with the consensus rating being Buy. The average one-year price target is $13.0, indicating a potential 1081.82% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of  and Tonix Pharmaceuticals, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for  and Tonix Pharmaceuticals, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tonix Pharmaceuticals</td>
<td>Outperform</td>
<td>-31.67%</td>
<td>$1.40M</td>
<td>-20.68%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Tango Therapeutics ranks at the bottom among its peers in terms of consensus rating. It also lags behind in revenue growth and gross profit. Additionally, its return on equity is lower compared to its peers.</p>
<h3>Discovering Tango Therapeutics: A Closer Look</h3>
<p>Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.</p>
<h3>Financial Insights: Tango Therapeutics</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Tango Therapeutics faced challenges, resulting in a decline of approximately <strong>-24.19%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Tango Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-914.99%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Tango Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-17.57%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-11.26%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Tango Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.18</strong>.</p>
<p><a href="https://www.benzinga.com/quote/TNGX/earnings"><strong>To track all earnings releases for Tango Therapeutics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Comments

Lightspeed Commerce

매도 수량

Lightspeed Commerce (NYSE:LSPD) 주식, 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌